Zhang J, et al. - Researchers, in this 1-year prospective study, studied the advantageous effects of zoledronic acid infusion combined with percutaneous kyphoplasty (PKP) in the treatment of T12 or L1 osteoporotic vertebral compression fracture (OVCF) in postmenopausal women. Females were randomized into 2 categories viz, zoledronic acid (ZOL) group (n = 50) or a control group (n = 51) with no statistically significant difference in age, height, weight, body mass index (BMI), menopause age, and the fractured vertebral body. Higher bone mineral density (BMD) in the ZOL group was higher recorded than that in the control group at 6 and 12 months after treatment whereas bone markers (NMID, P1NP, and β-CTX) and the VAS score in ZOL group were significantly lower when compared to the control group. They did not detect recompression vertebral fracture (RVF) in any patient in the ZOL group but, the incidence of RVF in the control group was 11.7%. They overall suggested ZOL IV infusion in combination with PKP beneficial for T12 or L1 OVCF treatment.